Continue to advance hypoimmune technology in three trials across five indications in type 1 diabetes, B-cell...
Prioritize clinical and preclinical development on type 1 diabetes (UP421 and SC451), B-cell mediated...
Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and...
Invaio Sciences Appoints Andrรฉ Andonian as Chairman of the Board of Directors PR Newswire CAMBRIDGE, Mass...
SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on...
SEATTLE, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on...
SEATTLE, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on...
Continue to advance hypoimmune technology in four trials across seven indications in oncology, B-cell mediated...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.